<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221202056687N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-15</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>"Effect of Pulsed Electromagnetic Field and Exercise Therapy in treatment of Osteoporosis"</public_title>
      <acronym>PEMF</acronym>
      <scientific_title>Effects of Application of Pulsed Electromagnetic Field and Therapeutic Exercise on Bone Mineral Density and Metabolism, and Quality of Life in Postmenopausal Osteoporotic Women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67169</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to randomly assign patients, sealed envelopes containing the words "pulsed electromagnetic field" or "therapeutic exercise" or "combination of pulsed electromagnetic field + therapeutic exercise" will be prepared. After flipping the cards, the clinic secretary clinic will randomly select one of the envelopes for each patient. The use of this method guarantees randomization, Blinding description: This study is single-blinded study, which means that an experience physiotherapist do the  intervention and another physiotherapist will do the evaluations. As a result, the evaluator will not know which group the patient belongs to.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Osteoporosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Pulse Electro Magnetic field. Intervention 2: Intervention group: Exercise therapy. Intervention 3: Intervention group: Pulsed Electromagnetic field+Exercise therapy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
If needed by the researchers and their request, the raw data of the research and
Its analysis will be provided to researchers

When:
After the publication of the articles resulting from the research

To whom:
Researchers working in academic institutions

Conditions:
The data is only available to other researchers to study and review treatment results
Placed

Where to obtain:
By sending an email to the corresponding author

How to obtain:
Send an email to the responsible author and request the document

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azadeh Shadmehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Enghelab St., Faculty of Rehabilitation Sciences, Department of Physiotherapy</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1148956111</zip>
        <telephone>+98 21 7753 5132</telephone>
        <email>shadmehr@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Sangtarash</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Enghelbal St., Faculty of Rehabilitation Sciences, Department of Physiotherapy</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1148956111</zip>
        <telephone>+98 21 7753 5</telephone>
        <email>f-sangtarash@razi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2></country2>
    </countries>
    <criteria>
      <inclusion_criteria>women at the age of 55-68, having reached menopause at least 5 year before the study.
A body mass index of 22-30
T-score for the hip or lumbar spine -2.5 SD or less.
do not have a history of overioectomy syrgery
Do not have a history of osteoporosis fracture</inclusion_criteria>
      <agemin>55 years</agemin>
      <agemax>68 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Participating in sports regularly for at least one year before starting the study (regular exercise means at least 30 minutes a day and 3 days a week)
Taking drugs that affect bone metabolism, except for daily calcium and vitamin D  and weekly alendronite tablets, which will be prescribed by the rheumatology consultant of the study with the same dose for all participants.
The presence of any medical problem affecting the person's movement (diabetes - diseases of the vestibular system - uncorrected vision or hearing disorders - neurological diseases
A history of surgery in the spine and pelvis and the use of tools to fix it or a history of surgery in the lower limbs
• History of hormone therapy in the last 6 months
A history of having cardiovascular diseases, such as uncontrolled blood pressure, which will be considered as an exclusion criterion for groups that will do exercise therapy
Using physiotherapy modalities effective on bone metabolism, such as using WBV, LPL, PEMF modalities in the last 6 month
Using tranquilizers (Tranquillizer) in both minor classifications (anti-anxiety, diazepam, oxazepam, alprazolam, etc.) and major (antipsychotic drugs such as haloperidol, phenotazines, fluphenazine, etc.) in three last month
Unwillingness of the samples to continue the treatment and not participating regularly in the treatment program
A change in sample conditions that would result in missing one of the inclusion criteria</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M81.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Age-related osteoporosis without current pathological fracture</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Pulse Electro Magnetic field</i_keyword>
      <i_keyword>Intervention group: Exercise therapy</i_keyword>
      <i_keyword>Intervention group: Pulsed Electromagnetic field+Exercise therapy</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bone mineral Density. Timepoint: At the beginning of the intervention and 12 weeks after the end of the intervention. Method of measurement: The use of X-Ray absorption method with dual energy DXA will be measured using the HOLOGENIC QDR1000 devic.</prim_outcome>
      <prim_outcome>Bone Turnover markers-bone specific alkalin phosphatase(BSALP). Timepoint: Before the start of the intervention - immediately after the end of the intervention - after a 12-week follow-up from the end of the intervention. Method of measurement: Blood test and examination of blood sample with the laboratory method of ELISA.</prim_outcome>
      <prim_outcome>Bone Turnover markers-N- terminal   telopeptide of    type 1 collagen. Timepoint: Before the start of the intervention - immediately after the end of the intervention - after a 12-week follow-up from the end of the intervention. Method of measurement: Blood test and examination of blood sample with the laboratory method of ELISA.</prim_outcome>
      <prim_outcome>Quality of life. Timepoint: Before the start of the intervention - immediately after the end of the intervention - after a 12-week follow-up from the end of the intervention. Method of measurement: Quality Of Life Questionnaire Of European Foundation for Osteoporosis.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Thoracic kyphosis. Timepoint: before and after the intervention (12 weeks later) ,and 12 weeks follow up after the end of the intervention. Method of measurement: Photogrammetry method.</sec_outcome>
      <sec_outcome>Lumbar lordosis. Timepoint: before and after the intervention (12 weeks later) ,and 12 weeks follow up after the end of the intervention. Method of measurement: Photogrammetry  method.</sec_outcome>
      <sec_outcome>Functional Balance. Timepoint: before and after the intervention (12 weeks later) ,and 12 weeks follow up after the end of the intervention. Method of measurement: Functional balance study with Timed Up and Go (TUG), Unilateral Stance Test(USL).</sec_outcome>
      <sec_outcome>Muscle Strenght. Timepoint: before and after the intervention (12 weeks later) ,and 12 weeks follow up after the end of the intervention. Method of measurement: Using micro manual muscle tester.</sec_outcome>
      <sec_outcome>Fear of falling. Timepoint: before and after the intervention (12 weeks later) ,and 12 weeks follow up after the end of the intervention. Method of measurement: persian version of Falls Efficacy Scale-International Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-11</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Faculty of Rehabilitation Sciences, Enghelab St., Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
